ID   FHS004i-sh12022C
AC   CVCL_YY35
SY   iPSC - 12022C
DR   BioSample; SAMN06093746
DR   GEO; GSM2411800
DR   WiCell; fhs004i-sh12022c
DR   Wikidata; Q98126039
RX   PubMed=28388431;
CC   Part of: Framingham Heart Study (FHS) collection.
CC   Part of: Next Generation Genetic Association studies (Next Gen) program cell lines.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_YY34 ! FHS003i-sh12022B
SX   Female
AG   51-60Y
CA   Induced pluripotent stem cell
DT   Created: 02-07-20; Last updated: 29-06-23; Version: 7
//
RX   PubMed=28388431; DOI=10.1016/j.stem.2017.01.010;
RA   Warren C.R., O'Sullivan J.F., Friesen M., Becker C.E., Zhang X.-L.,
RA   Liu P.-C., Wakabayashi Y., Morningstar J.E., Shi X., Choi J., Xia F.,
RA   Peters D.T., Florido M.H.C., Tsankov A.M., Duberow E.A., Comisar L.,
RA   Shay J., Jiang X., Meissner A., Musunuru K., Kathiresan S.,
RA   Daheron L., Zhu J., Gerszten R.E., Deo R.C., Vasan R.S.,
RA   O'Donnell C.J., Cowan C.A.;
RT   "Induced pluripotent stem cell differentiation enables functional
RT   validation of GWAS variants in metabolic disease.";
RL   Cell Stem Cell 20:547-557.e7(2017).
//